Last reviewed · How we verify
(Arm Closed) Tinzaparin
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Venous thromboembolism prophylaxis and treatment, Acute coronary syndrome.
At a glance
| Generic name | (Arm Closed) Tinzaparin |
|---|---|
| Sponsor | University of Melbourne |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa, Thrombin (Factor IIa) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Tinzaparin is derived from unfractionated heparin through chemical depolymerization, resulting in a mixture of polysaccharide chains with molecular weights between 5,000 and 10,000 Daltons. It potentiates antithrombin III-mediated inhibition of coagulation factors, particularly factor Xa, with a higher anti-Xa to anti-IIa activity ratio compared to unfractionated heparin. This selective inhibition of the coagulation cascade prevents thrombus formation and propagation.
Approved indications
- Venous thromboembolism prophylaxis and treatment
- Acute coronary syndrome
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |